OBJECTIVES: Cardiovascular diseases (CVDs) are the leading cause of death/disability in Qatar. Nonetheless, there are no any Qatari data that describes the patterns of using drugs for the CVD. This study sought to assess changes in the ‘utilization’ and ‘expenditures’ of cardiovascular drugs over time.  METHODS: The study is conducted from the Hamad Medical Corporation (HMC) setting, whereby utilization and expenditures data were obtained from HMC drug databases that are based on the 2007- 2011 period. Data were categorized by drug, drug concentration, drug class, year, and hospital. Descriptive statistics were used to illustrate distributions of variables, and cross-tabulation was used to provide comparison of frequency data. RESULTS: An increasing trend in utilization and expenditures was associated with the use of cardiovascular drugs. The rise in expenditure was more substantial as compared to utilization however. Hamad General, in HMC, was the major consumer of cardiovascular drugs. The class with the most significant (and highest utilization) in HG was the statins (p-value 0.04). Among statins, atorvastatin was increasingly the most used. An identical pattern of expenditures to that of utilization was observed for all drug classes. Apart from all combination therapies, the combining of angiotensin-receptor-blockers with diuretics was the only one increasing in use. CONCLUSIONS: Utilization and expenditures of cardiovascular drugs have steadily increased over the past 5 years in Qatar. Reasons for increasing trends in utilization can include fast growing population, in addition to newer clinical trial evidences as well as updated guidelines.